A B S T R A C T We examined in rats the effects of intraperitoneal angiotensin II (All) infusion for 12 d on urinary excretion, plasma concentration, and in vitro release of prostaglandin (PG) E2 and 6-keto-PGFI,,, a PGI2 metabolite. AII at 200 ng/min increased systolic blood pressure (SBP) progressively from 125±3 to 170±9 mmHg (P < 0.01) and elevated fluid intake and urine volume. Urinary 6-keto-PGF,a excretion increased from 38±6 to 55±5 and 51±7 ng/d (P < 0.05) on days 8 and 11, respectively, of All infusion, but urinary PGE2 excretion did not change. Relative to a control value of 129±12 pg/ml in vehicle-infused (V) rats, arterial plasma 6-keto-PGFi,a concentration increased by 133% (P < 0.01) with All infusion. Aortic rings from AII-infused rats released more 6-keto-PGF1, (68±7 ng/mg) during 15-min incubation in Krebs solution than did rings from V rats (40±3 ng/ mg); release of PGE2, which was <1% of that of 6-keto-PGFI,a, was also increased. Slices of inner renal medulla from AII-infused rats released more 6-ketoPGFia (14±1 ng/mg) during incubation than did slices from V rats (8±1 ng/mg, P < 0.05), but PGE2 release was not altered. In contrast, AII infusion did not alter release of 6-keto-PGFI,, or PGE2 from inferior vena cava segments or from renal cortex slices. Infusion of AII at 125 ng/min also increased SBP, plasma 6-ketoPGFia concentration, and in vitro release of 6-ketoPGFia from rings of aorta and renal inner medulla slices; at 75 ng/min AII had no effect. SBP on AII infusion day 11 correlated positively with both 6-ketoPGFia plasma concentration (r = 0.54) and net aortic Address all correspondence to Dr. Alberto Nasjletti. Dr. Diz' current address is Building 10, Room 3D-48, National Institutes of Mental Health, Bethesda, MD 20205. Received for publication I June 1982 and in revised form 6 April 1983. ring release (r = 0.70) when data from all rats were combined. We conclude that augmentation of PGI2 production is a feature of AII-induced hypertension. The enhancement of PGI2 production may be an expression of nonspecific alteration in vascular structure and metabolic functions during AII-induced hypertension, as well as the result of a specific effect of the peptide on the arachidonate-prostaglandin system.
INTRODUCTION
The concept that an interplay between prostaglandins (PG)' and angiotensin II contributes to circulatory homeostasis was first advanced in 1970 by McGiff et al. (1) , who reported release of a PG-like substance into renal venous blood in response to arterial angiotensin II infusion. Subsequently, this notion gained strength with reports that the vascular effects of angiotensin II are augmented by prostaglandin synthetase inhibitors (2) (3) (4) and attenuated by both PGE2 and PGI2 (5, 6) and that, in conditions featuring activation of the renin-angiotensin system, the administration of prostaglandin synthetase inhibitors causes renal vasoconstriction that is correlated positively with the level of plasma renin activity (7) . It is now also established that angiotensin II can promote release of PG from a variety of organs, including kidneys (1, 2, 8) , lungs (9, 10) , heart (3, 11) , and blood vessels (12, 13) , and that this action is due to stimulation of PG biosynthesis (11) . However, much of the information on the effects of angiotensin II on PG biosynthesis is derived from shortterm studies of isolated perfused organs or of anesthetized animals subjected to surgical stress and may not, consequently, be applicable to more physiological settings. For example, it is conceivable that the PG response of a tissue or organ to a brief and localized increase in angiotensin II varies from the response to a prolonged and systemic increase; in the latter case the response may vary with time, and be affected by the many functional and metabolic alterations that are associated with chronic increases in angiotensin II levels. If so, any further consideration of an angiotensin II-PG interplay in long-term regulation of physiological events requires information on the consequences of prolonged elevation of angiotensin II levels on the PG system. The present study in conscious rats was, therefore, designed to assess the effects of chronic angiotensin II administration on the urinary excretion, plasma concentration, and in vitro tissue release of PGE2 and 6-keto-PGFIa; the latter arises from nonenzymatic hydrolysis of PGI2 (11) , and is viewed as an expression of PGI2 levels and production.
METHODS
Experiments were performed on 51 male Wistar rats (Harlan Sprague Dawley, Inc., Indianapolis, IN) weighing 231-290 g; 27 of the rats were housed in individual metabolism cages, and the remainder were maintained in group cages with three to five rats per cage. The rats were kept in a temperature (24°C)-and humidity (50%)-controlled room that was illuminated between 6:00 a.m. and 6:00 p.m., had free access to tap water, and were fed ad lib. a standard chow (Purina No. 5001, Ralston Purina Co., St. Louis, MO) containing sodium (174 meq/kg) and potassium (282 meq/kg).
Protocol. Studies were performed after a 7-d period of acclimatization of the rats to the housing, feeding, and drinking conditions. Following a subsequent 4-d control period, each animal was anesthetized with ether and an Alzet osmotic minipump (model 2002, Alza Corp., Palo Alto, CA) filled with angiotensin II solution or vehicle was placed in the abdominal cavity through a 1-cm midline incision, which was then closed with autoclips. Isoleucine5-angiotensin II (Sigma Chemical Co., St. Louis, MO) was dissolved to different concentrations in 0.01 N acetic acid. Rats serving as time controls received only 0.01 N acetic acid. Assuming that the angiotensin II did not degrade during the study, and that the pumps dispensed fluid at the specified rate of 0.49 ;J/h, the calculated infusion rates of angiotensin II were 75, 125, and 200 ng/min, in 9, 4, and 19 rats, respectively. Aguilera et al. (14) reported that intraperitoneal angiotensin II infusion at doses ranging from 50 to 250 ng/min elevated the concentration of angiotensin II in blood by about threeto 40-fold after 36 h of infusion.
Systolic blood pressure and body weight were determined in all rats during the control period and at intervals after implantation of the minipumps: in rats housed in individual metabolism cages, 24-h food and electrolyte consumption, water intake, urine volume, and urinary excretion of sodium, potassium, PGE2, and 6-keto-PGFI. were also determined.
Urine was collected for 24-h periods at room temperature except during measurement of PG excretion, in which case the urine was received in plastic bottles surrounded by dry ice to keep the specimens frozen throughout the collection period.
On day 4 or 12 of the infusion period, the rats were anesthetized with ether and the abdomen was opened with a midline incision. The abdominal aorta was punctured and a 4-6-ml blood sample was collected into a syringe containing 15% EDTA (100 ju) and indomethacin ( To extract PG from plasma the specimen (2-3 ml) was acidified to pH 3.0 with formic acid and applied to an octadecylsilyl silica column that was eluted as described above for urine samples. The methyl formate fraction containing the prostanoids was evaporated to dryness under nitrogen and the lipid residue was dissolved in methanol, applied as a band to a 0.25-mm thick silica gel G thin-layer chromatography plate (Redi-Plate, 20 X 20 cm, Fisher Scientific Co., Pittsburgh, PA), and chromatographed concurrently with authentic prostanoid standards, using as a solvent system the organic phase of ethyl acetate/isooctane/acetic acid/water (11:5:2:10, vol/vol). Authentic PG were located by exposing the plate to iodine vapor. Zones of the plate corresponding to the position of PGE2 and 6-keto-PGFI,,, were scraped off and eluted with methanol. The eluates were dried in nitrogen and the lipid residues were reconstituted in radioimmunoassay buffer and assayed for PGE2 and 6-keto-PGFIa, respectively. The recovery of [3H]PGE2 and 6-keto-[3H]PGFIa added to each plasma sample before purification was 68.3±2.5 and 55.9±3.1%, respectively. The individual recovery values served to correct the estimates of plasma PGE2 and 6-keto-PGF1,, for losses incurred during purification. The plasma levels of PGE2 and 6-keto-PGF1,, are expressed as picograms per milliliter. The coefficient of variation of PG assays on 7 different days in the same sample of plasma was 14.2% for PGE2 and 13.0% for 6-keto-PGFIa.
Radioimmunoassay of 13,14-dihydro-15-keto-PGE2. The concentration of this metabolite of PGE2 in plasma was measured in unextracted specimens with an antiserum donated by Dr. Lawrence Levine (16) ; the plasma levels are expressed in picograms per milliliter. The intraassay coefficient of variation was 7.6%.
Systolic blood pressure determination. Systolic blood pressure was determined by tail sphygmography after warming the rats at 37°C for 10-15 min.
Urinary electrolytes and osmolality determinations. Sodium and potassium concentration in urine was determined by flame photometry with lithium as the internal standard, and urine osmolality was determined by freezing point depression.
Statistical analyses. 
RESULTS
The effect of intraperitoneal infusion of angiotensin II on systolic blood pressure and body weight is shown in Fig. 1 Table I are fluid intake and urine volume, osmolality, and electrolyte values. Coincident with the increase in blood pressure, animals receiving angiotensin II at 200 ng/min exhibited a two-to threefold elevation in urine volume that was associated with a substantial increase of water intake, and a lowering of urinary osmolality to about one-third of the preinfusion value. The daily dietary intake of sodium and potassium was reduced throughout the period of administration of angiotensin II at 200 ng/min, and the urinary excretion of these electrolytes was either unchanged or decreased relative to values in vehicle-infused rats. However, for both sodium and potassium the difference between dietary intake and urinary excretion tended to fall in the rats infused with angiotensin II at 200 ng/min, suggesting reduced retention. Infusion of angiotensin II at 75 ng/min had no effect on any of the above discussed variables. Plasma PG levels measured in arterial blood on the 12th d of infusion are displayed in Fig. 3 . The level of immunoreactive 6-keto-PGFIa increased by -'55% (P < 0.05) and 133% (P < 0.01) with the administration of angiotensin II for 12 d at 125 and 200 ng/min, respectively, relative to a control value of 129±12 pg/ ml in vehicle-infused rats. The plasma level of 6-keto-PGF1, also was higher (P = 0.05) in rats receiving angiotensin II for 4 d at 200 ng/min (152±19 pg/ml; n = 5) than in animals receiving vehicle only (98±14 pg/ml; n = 5). Plasma PGE2 concentration was not affected by angiotensin II infused at 75 or 125 ng/min for 12 d, but tended to increase the rats infused at 200 ng/min (0.01 < P < 0.1). The plasma concentration of 13,14-dihydro-15-keto-PGE2 in rats infused with angiotensin II for 12 d at 200 ng/min, but not at 75 ng/min, was higher (P < 0.05) than the concentration in animals receiving vehicle only. Linear regression analysis of combined data from the vehicle-infused rats and all three groups of rats infused with angiotensin II for 12 d revealed a positive correlation between plasma 6-keto-PGF1, concentration and systolic blood pressure (r = 0.54; P < 0.01; y = -91.7 + 1.92x).
Net release of PG from vascular tissues during incubation in Krebs solution for 15 min is illustrated in Fig. 4 (ng/min) FIGURE 4 Net release of immunoreactive 6-keto-PGF1. 6 -keto-PGFia than did slices from vehicle-infused rats. In contrast, the net release of PGE2 from inner medulla slices was not affected. Similarly, neither PGE2 nor 6-keto-PGFia release from renal cortex slices obtained from angiotensin II-infused rats differed significantly from corresponding values for slices from vehicle-infused rats.
DISCUSSION
PGE2 in the urine arises within the kidney (17) and its rate of excretion is a function of renal PGE2 synthesis (18) . In the present study a chronic infusion of angiotensin II did not affect either urinary PGE2 excretion or net release of PGE2 from renal tissue in vitro, suggesting that the renal production of PGE2 did not increase. These findings appear to be at variance with reports that angiotensin II promotes renal PGE2 synthesis and release. However, all such prior reports have been restricted to the effects on PG synthesis of short-term angiotensin II administration and the results, therefore, can not be considered to conflict directly with those of our present chronic infusion study. Further, data contained in two early reports (1, 8) of the effect of close renal arterial infusion of angiotensin II on renal PG show that renal PGE2 release was augmented initially, but that the effect was not sustained. Rather, the angiotensin II infusion was shown to induce prompt rises in urinary PGE2 excretion and renal venous blood PGE2 concentration, and both tended to return to or toward control levels after several minutes of continued infusion.
Contrasting with the lack of effect of chronic angiotensin II infusion on urinary PGE2 excretion, the urinary output of 6-keto-PGFia increased during anAngiotensin II Effects on Prostaglandins 473 giotensin II administration. Urinary 6-keto-PGFia may arise both from glomerular ultrafiltration of plasma (19) and from several renal cell types (20, 21) . There- fore, the augmentation of urinary 6-keto-PGF,a excretion may have resulted from both stimulation of renal PGI2 synthesis and elevation of the plasma concentration of PGI2 and/or 6-keto-PGFia. Values are means±SE, n = number of observations, the asterisk denotes significant difference from value used in vehicle-infused rats (P < 0.05); angiotensin II (All) or vehicle were infused for 12 d before the study.
in dogs was attributed to stimulation of PGI2 synthesis in the lungs (10, 22) and kidneys (22, 23) . The plasma level of 13,14-dihydro-15-keto-PGE2 increased with administration of angiotensin II suggesting stimulation of PGE2 tissue production. Metabolism of PGE2 to 13,14-dihydro-15-keto-PGE2, which occurs readily in the lung and in other tissues, may have prevented the arterial plasma concentration of PGE2 from rising during angiotensin infusion (24) . In this present study we found that rings of aorta from rats infused with angiotensin II for 12 d released more 6-keto-PGFia than did rings from vehicle-infused rats, suggesting augmentation of arterial vascular PGI2 synthesis in rats receiving angiotensin II. However, PGI2 synthesis by the aorta need not be representative of that by other vascular segments, in particular the microvasculature. Although rings of aorta from angiotensin II-infused rats also released more PGE2 than did rings from vehicle-infused rats, it should be noted that the amount of PGE2 released was <1% of the amount of 6-keto-PGFia released.
Overall, our data on the urinary excretion, plasma concentration, and in vitro tissue release of 6-keto-PGF1,a suggest that augmentation of renal and extrarenal PGI2 production and, presumably, plasma PGI2 concentration is a feature of the response of the intact rat to chronic infusion of angiotensin II. Information derived from acute studies indicates that the action of angiotensin II to increase PG synthesis relates to stimulation of phospholipid deacylation (25) , which increases the free arachidonic acid available to cyclooxygenase and, consequently, the formation of endoperoxide intermediates and PG. Induction of PG synthesis by angiotensin is characterized by rapidity of onset and reversibility after removal of the stimulus (25) . Therefore, it is intriguing that in the present study angiotensin II did not increase the urinary excretion of 6-keto-PGFsa or the release of 6-keto-PGFs, from rings of aorta until after a lag period of several days. Furthermore, under in vitro conditions that did not preserve a critical feature of the in vivo environment, i.e., high angiotensin II levels, rings of aorta and renal medullary tissue obtained from rats infused with angiotensin II for 12 d still released more 6-keto-PGFsa than did corresponding tissues from vehicle-infused rats. These observations require consideration of the possibility that during chronic angiotensin II infusion the enhancement of urinary excretion and in vitro tissue release of 6-keto-PGFia relates to one or more slowly developing and persistent alterations in function and/or tissue structure rather than to a direct, immediate, and rapidly reversible action of angiotensin II on the phospholipid-arachidonate-prostaglandin system. In this respect, we found that angiotensin II caused a progressive elevation of blood pressure, the final level of which correlated positively on the 12th but not on the 4th d of infusion with the net release of 6-keto-PGFIa from aortic rings in vitro. Several other investigators have also noted an association between high blood pressure and increased vascular PG synthesis (26, 27) . Similarly, various features of renal PG metabolism have been found to be abnormal in other animal models of hypertension (28) (29) (30) . In our study, angiotensin II also produced substantial alterations in renal function, caloric intake, and electrolyte balance that conceivably could have contributed to the overall effect of the peptide on PG production. For example, there are reports that the renal synthesis of PGE2 is affected by changes in the intake of sodium (31) and potassium (32) , and that the vascular synthesis of PGI2 depends on extracellular potassium concentration (33) .
That chronic infusion of angiotensin II in the rat resulted in sustained hypertension confirms a recent report (34) . The tendency for the difference between sodium intake and urinary sodium excretion to fall during angiotensin administration at 200 ng/min suggests that renal sodium retention was reduced; this, Angiotensin II Effects on Prostaglandins and the associated rise in urine volume, may be related to pressure-induced diuresis and natriuresis.
This study was not designed to assess the functional significance of the increase in PG associated with angiotensin II-induced hypertension. However, it is well recognized that several PG are capable of affecting vascular and renal mechanisms involved in blood pressure regulation (35) . For example, both PGI2 and PGE2 dilate resistance blood vessels and attenuate vascular reactivity to angiotensin II and other pressor stimuli (6) . It follows, then, that increased PG production during chronic angiotensin II infusion may be part of a homeostatic response that acts to minimize the angiotensin II-induced blood pressure elevation.
In conclusion, our study shows that chronic angiotensin II infusion in rats produces a progressive increase in blood pressure associated with augmentation of plasma concentration, urinary excretion, and net in vitro release of 6-keto-PGFia from rings of aorta and slices of renal inner medulla. We found no evidence of increased renal PGE2 production during angiotensin II infusion. On the basis of these findings, we conclude that augmentation of PGI2 production is a feature of the response to angiotensin II-induced hypertension.
